Eileen Bostwick is an expert in the development of oral antibody products. Dr. Bostwick most recently was VP, Development and Quality Control at Avaxia before her retirement. Previously, she was VP, R&D at GalaGen Inc., a company that was spun out of Land O´Lakes to develop pharmaceutical products from bovine milk and colostrum. At GalaGen, she led the R&D, regulatory and clinical efforts to advance these products to human clinical testing. She managed all aspects of the development process, including immunizations and colostrum collection, QC and evaluation of raw materials, coordination of bulk manufacturing and analysis, establishment of product and process specifications, validation of analytical methods, development of preclinical testing protocols and interactions with the USDA, CFSAN and FDA. Since leaving GalaGen, she has been a consultant and VP, R&D at BioBalance Corp. Dr. Bostwick holds a Ph.D. in Animal Physiology from the University of Minnesota.
Dr. Kamen was president of Abbott Bioresearch Center and served on Abbott´s Executive Management Committee following its 2001 acquisition of BASF´s pharmaceutical business, where he was President, BASF Bioresearch Corporation for ten years. From 1982-1986, Dr. Kamen was Director of Research, VP Research and Senior VP, Scientific Affairs at Genetics Institute, Inc. Dr. Kamen has an A.B. (summa cum laude) in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University.
Dr. Sands is Chief of the Henry D. Janowitz Division of Gastroenterology at the Mount Sinai School of Medicine in NY. He was previously Associate Professor of Medicine at Harvard Medical School, Associate Physician, Co-Director of the Crohn´s and Colitis Center and Director of Clinical Research for the Gastrointestinal Unit at Massachusetts General Hospital. He is a member of the American Gastroenterological Association, and a Fellow of the American College of Gastroenterology. He is past Chairman of the Clinical Research Alliance of the Crohn´s & Colitis Foundation of America. Dr. Sands received his MD from Boston University School of Medicine.
Dr. Sonis is the Chief of the Division of Oral Medicine, Department of Surgery at the Dana-Farber Cancer Institute, Senior Physician, Oral and Maxillofacial Surgery and Dentistry, Brigham and Women's Hospital, and Professor of Oral Medicine, Infection and Immunity at Harvard. He is one of the world´s leading experts in mucositis research and clinical trials on the epidemiology, mechanisms, burden of illness, and novel interventions in patients receiving stem cell transplants or treatment for head and neck cancers and other solid tumors.
Daniel Tracey is an expert in the pre-clinical development of biologics, particularly anti-cytokine antibodies. Dr. Tracey was Vice President, Research, at Avaxia before his retirement. He continues to work with Avaxia as a part-time employee. Dr. Tracey has over 25 years of experience in drug discovery, translational medicine and early development in the pharmaceutical industry with Abbott Laboratories, BASF Pharma and The Upjohn Company, specializing in the role of TNF, IL-1, IL-12 and other cytokines in inflammatory diseases. At BASF/Abbott he was Director of immunology, pharmacology and biologics research in the discovery, characterization and development of Humira, a human monoclonal anti-TNF antibody for the treatment of Crohn's disease, rheumatoid arthritis and other diseases. Since his retirement from Abbott, Dr. Tracey has been a pharmaceutical research consultant, notably for BioAssets Development Corporation in the development of anti-TNF biologics for spinal indications, a program which led to partnering of the company with Cephalon. Dr. Tracey received a PhD in immunology from Johns Hopkins University, was a postdoctoral fellow at the Karolinska Institute in Stockholm and Assistant Professor of Medicine at the Johns Hopkins University School of Medicine before joining the pharmaceutical industry.